title: Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
abstract: Poorly differentiated endocrine carcinomas (PDEC) are usually treated with cisplatin-based chemotherapy regimens. We here present a case with a dramatic response (both radiologically and biochemically) to the combination of temozolomide and bevacizumab, after failure of cisplatin and etoposide, with continued tumor shrinkage at 5 months. Temozolomide combined with bevacizumab might be a good treatment option in PDEC, perhaps even in a first-line setting. Prospective studies to answer this are warranted.
authors.affiliation: Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden. daniel.lindholm@medsci.uu.se
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Lindholm
authors.forename: Barbro
authors.initials: B
authors.lastname: Eriksson
authors.forename: Dan
authors.initials: D
authors.lastname: Granberg
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary; D016879:Salvage Therapy / Q000379:methods*; D000077204:Temozolomide
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide